Small MoleculePopPKIVInfectious Disease

Voriconazole IV PopPK Model

Indication: Invasive Fungal Infections

Population PK simulator for IV voriconazole. Explore loading doses and steady-state trough targets.

Drug Overview

Clinical Context

Molecular Target
CYP51
Drug Class
Small Molecule
Therapeutic Area
Infectious Disease
Indication
Invasive Fungal Infections
Route of Administration
IV

Model Information

Model Type
2-cpt with nonlinear (Michaelis-Menten) elimination
Category
PopPK

This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.

Pharmacokinetic Parameters

PK Parameters

ParameterValue
Q14 L/h
CL4.6 L/h (70 kg, CYP2C19 EM)
Km3.0 mg/L (Michaelis-Menten)
Vc58 L
Vp98 L
Vmax18 mg/h
t half6-12 h (dose-dependent)

Additional Parameters

ParameterValue
ka oral1.0-2.0 h⁻¹

Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.

About This Simulator

This interactive pharmacokinetic simulator for Voriconazole IV allows you to explore concentration-time profiles under different dosing scenarios. The underlying PopPK model characterizes the pharmacokinetics of this small molecule following iv administration.

Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).

Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.

Frequently Asked Questions

What is the Voriconazole IV PK simulator?

This is a free, interactive pharmacokinetic simulator for Voriconazole IV used in Invasive Fungal Infections. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.

What drug class does Voriconazole IV belong to?

Voriconazole IV is classified as a Small Molecule that targets CYP51. It is used in the Infectious Disease therapeutic area.

What route of administration does this model simulate?

This simulator models IV administration of Voriconazole IV. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.

What type of PK model is used?

This simulator uses a PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.

Is this simulator free to use?

Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.

Can I use this for clinical dosing decisions?

No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.

What is the half-life of Voriconazole IV?

Based on the published model parameters, the elimination half-life of Voriconazole IV is approximately 6-12 h (dose-dependent). Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.

What is the clearance of Voriconazole IV?

The clearance (CL) of Voriconazole IV is approximately 4.6 L/h (70 kg, CYP2C19 EM). Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.

Related Simulators

Ready to Simulate?

Launch the Voriconazole IV simulator to explore dosing scenarios and pharmacokinetic profiles interactively.

🚀 Launch Simulator

Comments

0/2000
Loading comments...

⚠️ Disclaimer

This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.

Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community